U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900945) titled 'Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants' on Oct. 22.
Brief Summary: This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Intervention:
BIOLOGICAL: CM551
Participants will receive single subcutaneous doses of CM551 solution in a dose escalation format across 4 sequential SAD cohorts.
DRUG: Placebo
Participants will receive single ...